CYP2B6 SNPs are associated with methadone dose required for effective treatment of opioid addiction

Addiction Biology

Volumn 18, Issue 4, 2013, Pages 709-716

  Levran, Orna ^a   Peles, Einat ^b   Hamon, Sara ^a   Randesi, Matthew ^a   Adelson, Miriam ^b   Kreek, Mary Jeanne ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b Dr Miriam and Sheldon G Adelson Clinic for Drug Abuse   (Israel)

Author keywords

Ancestry informative markers; CYP2B6; Israel; methadone; opioid addiction; pharmacogenomics

Indexed keywords

ALANINE; CYTOCHROME P450 2B6; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; GLYCINE; METHADONE; THREONINE;

ALLELE; ARTICLE; DISEASE ASSOCIATION; DRUG METABOLISM; EUROPE; FEMALE; GENETIC VARIABILITY; GENOTYPE; HEROIN DEPENDENCE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; ISRAEL; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; AGED; ANALGESICS, OPIOID; ANALYSIS OF VARIANCE; ARYL HYDROCARBON HYDROXYLASES; DOSE-RESPONSE RELATIONSHIP, DRUG; ETHNIC GROUPS; FEMALE; GENE FREQUENCY; HETEROZYGOTE; HOMOZYGOTE; HUMANS; INDIVIDUALIZED MEDICINE; ISRAEL; LINKAGE DISEQUILIBRIUM; MALE; METHADONE; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; OXIDOREDUCTASES, N-DEMETHYLATING; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; SEQUENCE ANALYSIS, DNA; YOUNG ADULT;

EID: 84879462963     PISSN: 13556215     EISSN: 13691600     Source Type: Journal    
DOI: 10.1111/j.1369-1600.2011.00349.x     Document Type: Article

References (39)

1. Adelson M, Peles E, Bodner G, Kreek MJ, (2007) Correlation between high methadone doses and methadone serum levels in methadone maintenance treatment (MMT) patients. J Addict Dis 26: 15-26. (Pubitemid 46797091)
2. Atzmon G, Hao L, Pe'er I, Velez C, Pearlman A, Palamara PF, Morrow B, Friedman E, Oddoux C, Burns E, Ostrer H, (2010) Abraham's children in the genome era: major Jewish diaspora populations comprise distinct genetic clusters with shared Middle Eastern Ancestry. Am J Hum Genet 86: 850-859.
3. Behar DM, Yunusbayev B, Metspalu M, Metspalu E, Rosset S, Parik J, Rootsi S, Chaubey G, Kutuev I, Yudkovsky G, Khusnutdinova EK, Balanovsky O, Semino O, Pereira L, Comas D, Gurwitz D, Bonne-Tamir B, Parfitt T, Hammer MF, Skorecki K, Villems R, (2010) The genome-wide structure of the Jewish people. Nature 466: 238-242.
4. Buchard A, Linnet K, Johansen SS, Munkholm J, Fregerslev M, Morling N, (2010) Postmortem blood concentrations of R- and S-enantiomers of methadone and EDDP in drug users: influence of co-medication and p-glycoprotein genotype. J Forensic Sci 55: 457-463.
5. Bunten H, Liang WJ, Pounder DJ, Seneviratne C, Osselton D, (2010) OPRM1 and CYP2B6 gene variants as risk factors in methadone-related deaths. Clin Pharmacol Ther 88: 383-389.
6. Charlier C, Dessalles MC, Plomteux G, (2001) Methadone maintenance treatment: is it possible to adapt the daily doses to the metabolic activity of the patient? Ther Drug Monit 23: 1-3. (Pubitemid 32105957)
7. Crettol S, Deglon JJ, Besson J, Croquette-Krokar M, Hammig R, Gothuey I, Monnat M, Eap CB, (2006) ABCB1 and cytochrome P450 genotypes and phenotypes: influence on methadone plasma levels and response to treatment. Clin Pharmacol Ther 80: 668-681. (Pubitemid 44920225)
8. Crettol S, Deglon JJ, Besson J, Croquette-Krokkar M, Gothuey I, Hammig R, Monnat M, Huttemann H, Baumann P, Eap CB, (2005) Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment. Clin Pharmacol Ther 78: 593-604. (Pubitemid 41773635)
9. Dumaual C, Miao X, Daly TM, Bruckner C, Njau R, Fu DJ, Close-Kirkwood S, Bauer N, Watanabe N, Hardenbol P, Hockett RD, (2007) Comprehensive assessment of metabolic enzyme and transporter genes using the Affymetrix Targeted Genotyping System. Pharmacogenomics 8: 293-305. (Pubitemid 46477741)
10. Eap CB, Crettol S, Rougier JS, Schlapfer J, Sintra Grilo L, Deglon JJ, Besson J, Croquette-Krokar M, Carrupt PA, Abriel H, (2007) Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clin Pharmacol Ther 81: 719-728. (Pubitemid 46625109)
11. Foster DJ, Somogyi AA, Bochner F, (1999) Methadone N-demethylation in human liver microsomes: lack of stereoselectivity and involvement of CYP3A4. Br J Clin Pharmacol 47: 403-412. (Pubitemid 29161273)
12. Foster DJ, Somogyi AA, Dyer KR, White JM, Bochner F, (2000) Steady-state pharmacokinetics of (R)- and (S)-methadone in methadone maintenance patients. Br J Clin Pharmacol 50: 427-440.
13. Gerber JG, Rhodes RJ, Gal J, (2004) Stereoselective metabolism of methadone N-demethylation by cytochrome P4502B6 and 2C19. Chirality 16: 36-44. (Pubitemid 37532283)
14. Hodgkinson CA, Yuan Q, Xu K, Shen PH, Heinz E, Lobos EA, Binder EB, Cubells J, Ehlers CL, Gelernter J, Mann J, Riley B, Roy A, Tabakoff B, Todd RD, Zhou Z, Goldman D, (2008) Addictions biology: haplotype-based analysis for 130 candidate genes on a single array. Alcohol Alcohol 43: 505-515.
15. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C, (2007) Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116: 496-526. (Pubitemid 350116943)
16. Inturrisi CE, Verebely K, (1972a) Disposition of methadone in man after a single oral dose. Clin Pharmacol Ther 13: 923-930.
17. Inturrisi CE, Verebely K, (1972b) The levels of methadone in the plasma in methadone maintenance. Clin Pharmacol Ther 13: 633-637.
18. Kharasch ED, Bedynek PS, Park S, Whittington D, Walker A, Hoffer C, (2008) Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance. Clin Pharmacol Ther 84: 497-505.
19. Kharasch ED, Hoffer C, Whittington D, Sheffels P, (2004) Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther 76: 250-269. (Pubitemid 39221799)
20. Kreek MJ, (1973) Plasma and urine levels of methadone. Comparison following four medication forms used in chronic maintenance treatment. N Y State J Med 73: 2773-2777.
21. Kreek MJ, (2007) Introduction to addictive disorders: implications for pharmacotherapies. In:, Sibley DR, Hanin I, Kuhar M, Skolnick P, eds. Handbook of Contemporary Neuropharmacology, pp. 451-463. Hoboken, NJ: Wiley.
22. Kreek MJ, LaForge KS, Butelman E, (2002) Pharmacotherapy of addictions. Nat Rev Drug Discov 1: 710-726. (Pubitemid 37361544)
23. Lamba V, Lamba J, Yasuda K, Strom S, Davila J, Hancock ML, Fackenthal JD, Rogan PK, Ring B, Wrighton SA, Schuetz EG, (2003) Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR (constitutive androstane receptor) expression. J Pharmacol Exp Ther 307: 906-922. (Pubitemid 37494207)
24. Levran O, O'Hara K, Peles E, Li D, Barral S, Ray B, Borg L, Ott J, Adelson M, Kreek MJ, (2008) ABCB1 (MDR1) genetic variants are associated with methadone doses required for effective treatment of heroin dependence. Hum Mol Genet 17: 2219-2227. (Pubitemid 351916578)
25. Li Y, Kantelip JP, Gerritsen-van Schieveen P, Davani S, (2008) Interindividual variability of methadone response: impact of genetic polymorphism. Mol Diagn Ther 12: 109-124. (Pubitemid 351570866)
26. Lotsch J, Skarke C, Wieting J, Oertel BG, Schmidt H, Brockmoller J, Geisslinger G, (2006) Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. Clin Pharmacol Ther 79: 72-89. (Pubitemid 43069580)
27. Luo HR, Aloumanis V, Lin KM, Gurwitz D, Wan YJ, (2004) Polymorphisms of CYP2C19 and CYP2D6 in Israeli ethnic groups. Am J Pharmacogenomics 4: 395-401. (Pubitemid 40052848)
28. McCance-Katz EF, Sullivan LE, Nallani S, (2010) Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am J Addict 19: 4-16.
29. Miksys SL, Tyndale RF, (2002) Drug-metabolizing cytochrome P450s in the brain. J Psychiatry Neurosci 27: 406-415. (Pubitemid 36110781)
30. Miksys S, Tyndale RF, (2009) Brain drug-metabolizing cytochrome P450 enzymes are active in vivo, demonstrated by mechanism-based enzyme inhibition. Neuropsychopharmacology 34: 634-640.
31. Pond SM, Kreek MJ, Tong TG, Raghunath J, Benowitz NL, (1985) Altered methadone pharmacokinetics in methadone-maintained pregnant women. J Pharmacol Exp Ther 233: 1-6. (Pubitemid 15083518)
32. Scott SA, Edelmann L, Kornreich R, Erazo M, Desnick RJ, (2007) CYP2C9, CYP2C19 and CYP2D6 allele frequencies in the Ashkenazi Jewish population. Pharmacogenomics 8: 721-730. (Pubitemid 47288973)
33. Shiran MR, Chowdry J, Rostami-Hodjegan A, Ellis SW, Lennard MS, Iqbal MZ, Lagundoye O, Seivewright N, Tucker GT, (2003) A discordance between cytochrome P450 2D6 genotype and phenotype in patients undergoing methadone maintenance treatment. Br J Clin Pharmacol 56: 220-224. (Pubitemid 36981438)
34. Shiran MR, Lennard MS, Iqbal MZ, Lagundoye O, Seivewright N, Tucker GT, Rostami-Hodjegan A, (2009) Contribution of the activities of CYP3A, CYP2D6, CYP1A2 and other potential covariates to the disposition of methadone in patients undergoing methadone maintenance treatment. Br J Clin Pharmacol 67: 29-37.
35. Tolson AH, Li H, Eddington ND, Wang H, (2009) Methadone induces the expression of hepatic drug-metabolizing enzymes through the activation of pregnane X receptor and constitutive androstane receptor. Drug Metab Dispos 37: 1887-1894.
36. Totah RA, Sheffels P, Roberts T, Whittington D, Thummel K, Kharasch ED, (2008) Role of CYP2B6 in stereoselective human methadone metabolism. Anesthesiology 108: 363-374. (Pubitemid 351304229)
37. Wang JS, DeVane CL, (2003) Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro. Drug Metab Dispos 31: 742-747.
38. Zanger UM, Klein K, Saussele T, Blievernicht J, Hofmann MH, Schwab M, (2007) Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics 8: 743-759. (Pubitemid 47288975)
39. Zhou SF, Liu JP, Chowbay B, (2009) Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 41: 89-295.